We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+60.37%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.46B
AUM Growth
+$766M
Cap. Flow
-$128M
Cap. Flow %
-3.7%
Top 10 Hldgs %
44.87%
Holding
104
New
18
Increased
30
Reduced
19
Closed
12

Top Buys

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$55.7M
2
CELC icon
Celcuity
CELC
+$53M
3
ROIV icon
Roivant Sciences
ROIV
+$50M
4
PEN icon
Penumbra
PEN
+$47.4M
5
MRUS
Merus
MRUS
+$42M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$520M
2
SLNO
Soleno Therapeutics
SLNO
+$36.1M
3
AORT icon
Artivion
AORT
+$29.2M
4
BBNX
Beta Bionics
BBNX
+$23.1M
5
EOLS icon
Evolus
EOLS
+$22.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RYTM icon
1
Rhythm Pharmaceuticals
RYTM
$7.31B
$288M 8.33%
2,438,969
+20,670
+0.9% +$1.92M
ASND icon
2
Ascendis Pharma A/S
ASND
$17.1B
$216M 6.25%
1,088,501
+124,615
+13% +$23.2M
ACLX
3
DELISTED
Arcellx
ACLX
$203M 5.85%
2,468,353
-9,647
-0.4% -$694K
CELC icon
4
Celcuity
CELC
$4.31B
$146M 4.22%
2,956,319
+1,323,111
+81% +$53M
NUVL
5
DELISTED
Nuvalent
NUVL
$135M 3.9%
1,562,336
+187,156
+14% +$14.8M
MRUS
6
DELISTED
Merus
MRUS
$127M 3.68%
1,353,093
+644,917
+91% +$42M
AMLX icon
7
Amylyx Pharmaceuticals
AMLX
$1.97B
$122M 3.51%
8,952,365
+1,050,000
+13% +$9.88M
ROIV icon
8
Roivant Sciences
ROIV
$24.8B
$111M 3.22%
7,368,461
+4,036,996
+121% +$50M
MGTX icon
9
MeiraGTx Holdings
MGTX
$1.15B
$104M 3%
12,626,103
– –
INSM icon
10
Insmed
INSM
$23.5B
$101M 2.92%
702,130
+51,878
+8% +$6.36M
TVTX icon
11
Travere Therapeutics
TVTX
$5.27B
$90.7M 2.62%
3,794,615
+2,960,363
+355% +$55.7M
AORT icon
12
Artivion
AORT
$1.22B
$85.5M 2.47%
2,020,000
-773,703
-28% -$29.2M
PRAX icon
13
Praxis Precision Medicines
PRAX
$8.77B
$82.9M 2.39%
1,564,554
+811,633
+108% +$39.4M
IMTX icon
14
Immatics
IMTX
$1.31B
$79.9M 2.31%
9,383,456
– –
CNTA
15
DELISTED
Centessa Pharmaceuticals
CNTA
$75.2M 2.17%
3,100,902
+1,953,967
+170% +$34.7M
SLDB icon
16
Solid Biosciences
SLDB
$858M
$73M 2.11%
11,833,539
-73,107
-0.6% -$427K
PTGX icon
17
Protagonist Therapeutics
PTGX
$9.06B
$68.4M 1.98%
1,030,134
-44,314
-4% -$2.52M
NBIX icon
18
Neurocrine Biosciences
NBIX
$17.2B
$63.2M 1.82%
450,050
+195,000
+76% +$26.4M
EWTX icon
19
Edgewise Therapeutics
EWTX
$4.28B
$61.6M 1.78%
3,795,894
-844,055
-18% -$12M
VRNA
20
DELISTED
Verona Pharma
VRNA
$55.9M 1.61%
524,088
-4,983,503
-90% -$520M
PEN icon
21
Penumbra
PEN
$12.5B
$55.9M 1.61%
220,547
+187,750
+572% +$47.4M
AKRO
22
DELISTED
Akero Therapeutics
AKRO
$53.9M 1.56%
1,135,766
+219,879
+24% +$10.6M
APGE icon
23
Apogee Therapeutics
APGE
$10.1B
$53.7M 1.55%
1,351,989
+169,841
+14% +$6.48M
OMDA
24
Omada Health Inc
OMDA
$1.41B
$53M 1.53%
2,396,330
-30,000
-1% -$614K
FOLD
25
DELISTED
Amicus Therapeutics
FOLD
$50.2M 1.45%
6,370,851
-1,041,979
-14% -$7.42M
1
2 3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2025 Portfolio in Review

As of Q3 2025, Perceptive Advisors held 104 positions worth $3.46B, up 28% from $2.7B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Perceptive Advisors withdrew a net $128M in Q3 2025, closing 12 positions and reducing 19 holdings. Its most notable exit was Soleno Therapeutics, an estimated $36.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, Perceptive Advisors opened a new position in Abivax worth $33M.

  • Perceptive Advisors's largest Q3 2025 buy was Abivax: 388,608 shares worth $33M.
  • Perceptive Advisors added most to Travere Therapeutics in Q3 2025, an estimated $55.7M increase.
  • Perceptive Advisors's biggest Q3 2025 reduction was Verona Pharma, cutting an estimated $520M.
  • Perceptive Advisors fully exited Soleno Therapeutics in Q3 2025, selling an estimated $36.1M.
  • Perceptive Advisors's ten largest holdings make up 45% of its $3.46B portfolio in Q3 2025.
  • Perceptive Advisors opened 18 new positions and closed 12 in Q3 2025.
  • Perceptive Advisors's portfolio value rose 28% quarter-over-quarter to $3.46B.

Based on Perceptive Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.